泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗活动性强直性脊柱炎的III期临床试验达到主要疗效终点

Core Viewpoint - Zai Lab (688266.SH) announced that its self-developed first-class new drug, JAK inhibitor (formerly known as Jackinib), has achieved its primary efficacy endpoint in a Phase III clinical trial for treating active ankylosing spondylitis, demonstrating statistical significance (p<0.0001) [1] Group 1 - The Phase III clinical trial titled "Efficacy and Safety of JAKinib in Patients with Active Ankylosing Spondylitis" met its primary efficacy endpoint [1] - The company plans to accelerate the market approval process for JAK inhibitor in treating active ankylosing spondylitis patients [1]